All In Biotech

Drug Trial Radar · NCT07458269

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

264

Actual

Start

Mar 4, 2026

Primary completion

May 2027

Study completion Jun 2027

Sponsor

Lead sponsor
KaileraIndustry
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

Conditions

  • Obesity

Interventions

  • RibupatideDrug

    SC Injection

  • PlaceboDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body Weight at Week 48Time frame: Baseline, Week 48

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Kailera Clinical Site

    Mesa, Arizona

  • Kailera Clinical Site

    Sun City West, Arizona

  • Kailera Clinical Site

    Irvine, California

  • Kailera Clinical Site

    Lake Forest, California

  • Kailera Clinical Site

    Lomita, California

  • Kailera Clinical Site

    Long Beach, California

  • Kailera Clinical Site

    Montclair, California

  • Kailera Clinical Site

    Rolling Hills Estates, California

  • Kailera Clinical Site

    San Diego, California

  • Kailera Clinical Site

    Santa Ana, California

  • Kailera Clinical Site

    Van Nuys, California

  • Kailera Clinical Site

    DeLand, Florida

  • Kailera Clinical Site

    Orlando, Florida

  • Kailera Clinical Site

    Orlando, Florida

  • Kailera Clinical Site

    The Villages, Florida

  • Kailera Clinical Site

    Decatur, Georgia

  • Kailera Clinical Site

    Woodstock, Georgia

  • Kailera Clinical Site

    Morton, Illinois

  • Kailera Clinical Site

    Indianapolis, Indiana

  • Kailera Clinical Site

    Louisville, Kentucky

  • Kailera Clinical Site

    Rockville, Maryland

  • Kailera Clinical Site

    St Louis, Missouri

  • Kailera Clinical Site

    Lincoln, Nebraska

  • Kailera Clinical Site

    Omaha, Nebraska

  • Kailera Clinical Site

    East Syracuse, New York

  • Kailera Clinical Site

    Greensboro, North Carolina

  • Kailera Clinical Site

    Monroe, North Carolina

  • Kailera Clinical Site

    Raleigh, North Carolina

  • Kailera Clinical Site

    Greenville, South Carolina

  • Kailera Clinical Site

    Myrtle Beach, South Carolina

  • Kailera Clinical Site

    Knoxville, Tennessee

  • Kailera Clinical Site

    Memphis, Tennessee

  • Kailera Clinical Site

    Garland, Texas

  • Kailera Clinical Site

    San Antonio, Texas

  • Kailera Clinical Site

    Winchester, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.